**Association between bisphosphonate therapy and outcomes from rehabilitation in older people**

**Abstract**

*Background*

Bisphosphonate therapy may have actions beyond bone, including effects on cardiovascular, immune and muscle function. We tested whether bisphosphonate treatment is associated with improved outcomes in older people undergoing inpatient rehabilitation

*Methods*

Analysis of prospectively collected, linked routine clinical datasets. Participants were divided into never users of bisphosphonates, use prior to rehabilitation only, use after rehabilitation only, and current users (use before and after rehabilitation). We calculated change in 20-point Barthel scores during rehabilitation, adjusting for comorbid disease and laboratory data using multivariable regression analysis. Cox regression analyses were performed to analyse the association between bisphosphonate use and time to death or hospitalisation.

*Results*

2797 patients were included in the analysis. Current bisphosphonate users showed greater improvement in Barthel score during rehabilitation than non-users (5.0 points [95%CI 4.3 to 5.7] vs 3.8 [95%CI 3.6 to 3.9]), but no difference compared to those receiving bisphosphonates only after discharge (5.1 [95%CI 4.6 to 5.5]). Previous bisphosphonate use was significantly associated with time to death (adjusted hazard ratio 1.41 [95%CI 1.15 to 1.73]) but less strongly with time to combined endpoint of hospitalisation or death (adjusted hazard ratio 1.18 [95%CI 0.98 to 1.48]). Use after discharge from rehabilitation was associated with reduced risk of death (adjusted hazard ratio 0.64 [95%CI 0.55 to 0.73]; hazard ratio per year of bisphosphonate prescription 0.98 [95%CI 0.97 to 0.99])

*Conclusion*

Bisphosphonate use is unlikely to be causally associated with improved physical function in older people, but continuing use may be associated with lower risk of death.

Keywords: Older, Bisphosphonate, rehabilitation, resilience

**Introduction**

Bisphosphonates are widely used as antiresorptive agents for treating osteoporosis. They bind to bone with high affinity, impairing the ability of osteoclasts to adhere to and resorb bone; they also promote apoptosis of osteoclasts, impair maturation of osteoclast progenitors, and hence reduce bone turnover and resorption. The consequent increase in bone mineral density reduces the relative risk of post-menopausal osteoporotic fractures by between 30 and 70%1. In addition, bisphosphonate therapy may have effects beyond reducing fracture rates; in a recent meta-analysis, bisphosphonate therapy reduced all-cause mortality by 10% in high-risk groups, an effect that appears much greater than can be attributed solely to their effect on fracture reduction2,3. Furthermore, the reduction in all-cause mortality is not driven by reductions in specific major event groups (e.g. cardiovascular events, cancer or infection) but appears to be distributed across multiple causes of death4.

Bisphosphonates have been shown to display a number of pleiotropic biological effects that might contribute to the above findings. First, nitrogen-containing bisphosphonates may exhibit actions on lipid metabolism similar to statin medications, via inhibition of the mevalonate pathway, thereby reducing the progression of atherogenic processes5-8. Statins themselves have been associated with improved outcomes from rehabilitation9,10. Related effects on the mevalonate pathway underlie alterations to lipid anchoring of a number of intracellular signalling molecules, which may explain the anticancer effects of bisphosphonates therapy observed in some studies. Effects on reducing oxidative stress have also been postulated; oxidative stress in turn has been linked to a wide range of disease states including cardiovascular disease11, cancer, and sarcopenia - the age-related loss of muscle mass and strength12,13. Bisphosphonates may also initially promote low-grade, chronic inflammation (via production of pro-inflammatory cytokines14,15) which in turn may activate protective mechanisms at a cellular level which protect against the consequences of more severe inflammation. Finally, recent preclinical data suggests that zoledronate can protect mesenchymal stem cells against the accumulation of DNA damage16.

Rehabilitation is an essential step on the pathway back to independent function for older people who have suffered intercurrent illness. Whilst it is recognised that rehabilitation is dependent on a number of factors, not least the quality and input of an exercise programme, it can be interrupted by further intercurrent illness with a consequent vicious cycle of immobility, worsening physical function and increased susceptibility to illness. Rehabilitation may also progress slowly due to intrinsic pathophysiological limitations like sarcopenia. Successful rehabilitation in older people might thus be enhanced by agents with pleiotropic effects on a variety of biological pathways to improve resilience; agents that improve muscle function directly would clearly be useful, but agents that either reduce intercurrent illness or mitigate the effects of intercurrent illness may also be of benefit. We therefore tested whether bisphosphonate treatment was associated with improved outcomes in a large cohort of older people undergoing inpatient rehabilitation, using routinely collected health and functional data.

**Methods**

*Data Sources and Patient Population*

This study was performed as part of a data linkage project which combined detailed healthcare data held on residents of Tayside, Scotland, held by the University of Dundee Health Informatics Centre (HIC) with functional outcome data on older people who had undergone inpatient rehabilitation within the Dundee Medicine for the Elderly service (DOME). Data linkage was achieved using the Community Health Index (CHI), a unique healthcare identifier assigned to all Scottish healthcare users. Data linkage was carried out by HIC, with the combined, anonymised dataset hosted in a safe haven facility, which allows analysis by permitted parties without release of raw data outside the safe haven facility.

The DOME functional outcome data forming the basis of this analysis has been described previously17,18. We used an extended version of this dataset, which was collected prospectively on all patients admitted for rehabilitation over a 13 year period between 1st January 1999 and 31st December 2011, and comprised approximately 5500 admissions on 4382 individuals. The HIC database is a comprehensive set of health data on 400,000 people within the Tayside, Scotland area. In this study, health data was extracted from the HIC database for those patients registered on the DOME database. Prescribing information, biochemistry and haematology results, hospitalization data and diagnoses (Scottish Morbidity Register 01) coded using ICD-10 codes were available. Data on date of death was obtained via the Scottish Government Records Office, which records all deaths registered in Scotland. For this analysis, the cohort consisted of patients undergoing their first admission to the rehabilitation service, and omitted repeat admissions to the rehabilitation service, so that effects of previous rehabilitation did not impact on either baseline function or response to rehabilitation.

*Bisphosphonate use*

Bisphosphonate use was defined by extracting prescription records for bisphosphonate medications contained in the British National Formulary. All bisphosphonates used in the study population were included, namely alendronate, risedronate, etidronate, clodronate and ibandronate. Zoledronic acid was not used within the service covered by this cohort during the time period under study. Data on prescribing are held only for prescriptions dispensed in the community, not in hospital; no electronic record exists for in-hospital prescriptions. We thus used community prescribing data from before and after each inpatient rehabilitation period to categorise patients into four groups: Current users comprised patients who were prescribed bisphosphonates at any time during the six months immediately prior and at any time in the 6 months subsequent to rehabilitation. Previous users comprised patients prescribed bisphosphonates in the two year period prior to rehabilitation, excluding those in group A. Subsequent users comprised patients who received bisphosphonates only after discharge from rehabilitation, and did not receive bisphosphonates in the two years prior to admission. Never users consisted of patients with no prescription for bisphosphonates recorded either before or after the rehabilitation stay at any point covered by the database (dating back to 01/01/1998 and censored at 04/05/2012). This approach allowed us to dissect out whether changes associated with bisphosphonate use were likely to be due to bisphosphonates, or due to unmeasured characteristics of patients who were more likely to be prescribed bisphosphonates. Relatively wide time windows were employed in part due to the known long duration of action of bisphosphonate medications, and because prescriptions for bisphosphonates are renewed infrequently due to the weekly dosing of many preparations.

*Measurement of functional status*

The functional outcome utilised in this study was the 20 point Barthel Index19, a widely used and validated measure of patients’ abilities in activities of daily living. The Barthel index consists of 10 separate function categories each with possible scores of 0/1, 0/1/2, or 0/1/2/3, yielding a total score out of 20, with a higher score indicating greater independence. A Barthel score was recorded by rehabilitation staff at admission and at discharge from inpatient rehabilitation. Discharge destination (coded as return to own home or elsewhere) was obtained from the rehabilitation dataset.

*Comorbidities and other covariates*

Covariates were selected on the basis of clinical plausibility and prior knowledge, based on their likelihood to interact with bisphosphonate therapy, affect rehabilitation outcome, physical function or susceptibility to illness. Age and sex were obtained from healthcare demographic information held within HIC data. Previous hospitalisation for myocardial infarction, stroke, COPD and heart failure were coded from ICD-10 codes held in HIC healthcare data. Previous diagnoses of cancer were obtained from SMR06 (Scottish Cancer Registry) data, and previous diagnoses of diabetes mellitus were obtained from the Scottish Care Information - Diabetes Collaboration (SCI-DC) database, which records all diagnoses of diabetes within Scotland. Renal function (recorded as estimated glomerular filtration rate [eGFR] and calculated by the Modified Diet in Renal Disease [MRDR4] equation20, serum calcium and serum albumin values were extracted from routinely collected biochemistry data held in HIC; the value closest to the date of admission to rehabilitation was used. Prescribed calcium and vitamin D supplementation was assessed by extraction of prescribing data in a similar way to bisphosphonate medication.

*Data Analysis*

Data analyses were performed using SPSS v21 (IBM, New York, USA) or SAS v9.2 (SAS Institute Inc., Cary, NC, USA). Patients who died during admission or had a missing admission or discharge Barthel score were excluded from analysis. Where patients had had multiple admissions to the rehabilitation service, only the first admission was included in the analysis, and subsequent admissions were ignored. Baseline factors were compared by bisphosphonate use, using one-way ANOVA for normally distributed continuous variables, Kruskal-Wallis test for non-normally distributed continuous variables, and Pearson’s Chi-squared test for categorical variables. The association between bisphosphonate use and improvement in Barthel score during rehabilitation was assessed by multivariable regression analysis, adjusting for age, sex, admission Barthel score, calcium/vitamin D use, renal function (eGFR), albumin, corrected calcium, previous diagnosis of diabetes mellitus, previous indication of IHD, stroke, cancer, COPD and CHF, and number of prescribed medications. A sensitivity analysis was conducted excluding those patients who had received non-aminobisphosphonates (clodronate or etidronate) due to their lack of effect on the mevalonate pathway. Because calcium and vitamin D are almost always co-administered with bisphosphonates, we analysed whether calcium and vitamin D use was associated with differences in rehabilitation outcomes, death or time to hospitalisation in the group of patients who had never taken bisphosphonates; if a significant effect were to be evident, the results of analyses of bisphosphonate exposure would not be reliably attributable to bisphosphonates. For those taking bisphosphonates prior to rehabilitation, the number of days of exposure in the year prior to rehabilitation was calculated – those on weekly preparations counted as 7 days per exposure, those on monthly preparations counted as 30 days per exposure. Adherence, which is known to be suboptimal with oral bisphosphonates, could not be directly calculated as data on encashed prescriptions was available, but date of decision to commence prescribing was not.

We conducted Cox regression analyses to estimate the association between bisphosphonate use and time to death after discharge from rehabilitation; similar analyses were conducted for time to a combined endpoint of death or next hospitalisation. For each analysis, models were run both unadjusted and adjusted for the variables listed above including discharge destination. Models were run comparing each of the groups against those patients never using bisphosphonates. To separate out the effect of previous exposure to bisphosphonates (which might be a marker for unmeasured frailty or comorbidity) from the effect of subsequent use, a separate analysis was run using any use prior to rehabilitation as a distinct variable from any use after discharge from rehabilitation. Further analyses were run using time-dependent Cox regression analyses; the cumulative exposure to bisphosphonates post-discharge was included as a time-dependent variable, with pre-admission exposure included as a categorical variable and other adjusting variables included as listed above.

**Results**

Data were available on 4382 first admissions to rehabilitation. 95 patients were omitted from the analysis because they had last received bisphosphonates greater than 2 years prior to admission. 366 patients died during their rehabilitation stay (27/392 [6.9%] of previous bisphosphonate users versus 339/3895 (8.7%) of never users, *p*=0.22). Of the remainder of the cohort, 1124 patients were excluded due to missing admission or discharge Barthel data. Analyses were therefore conducted on the remaining 2797 patients. Table 1 gives the baseline details for the four analysis groups.

No effect of calcium and vitamin D supplementation was evident on either rehabilitation outcomes (3.8 points vs 3.7 points improvement during rehabilitation, *p*=0.15), risk of death (hazard ratio 0.90, 95%CI 0.72 to 1.12), or risk of hospitalisation or death (hazard ratio 0.99, 95%CI 0.81 to 1.21) in the group of patients who had never used bisphosphonates. Calcium and vitamin D use was included as a covariate in all subsequent analyses. Table 2 shows the association between different patterns of bisphosphonate exposure and improvements seen in Barthel score during inpatient rehabilitation, giving both unadjusted results and results adjusted for the variables listed above. Excluding those patients who had used non-nitrogen-containing bisphosphonates (clodronate or etidronate) did not significantly change the results (adjusted improvement in Barthel scores for never, previous, current and subsequent users: 3.8 [3.6 to 3.9]; 3.7 [2.9 to 4.5]; 5.8 [4.9 to 6.6]; 5.1 [4.6 to 5.5]; p=0.17 for current vs subsequent users). Exposure to bisphosphonates in the year prior to rehabilitation varied, with 43% of those taking bisphosphonates prior to rehabilitation taking less than 180 days equivalent in the year prior to admission. However there was no significant correlation between the number of days of bisphosphonate use in the year prior to rehabilitation and the improvement in Barthel score (unadjusted r=-0.05, p=0.49; adjusted r=-0.12, p=0.15)

Table 3 gives the results of both unadjusted and adjusted Cox regression analyses, showing the effect of exposure to bisphosphonates post-discharge on both survival and time to the combined death or next hospitalisation endpoint. Time-dependent Cox regression analyses showed similar results; the adjusted hazard ratio for death post-discharge was 0.98 (95%CI 0.97 to 0.99) per year of post-discharge bisphosphonate exposure, and the adjusted hazard ratio for death or next hospitalisation post-discharge was 1.01 (95%CI 0.98 to 1.04) per year of post-discharge bisphosphonate exposure.

**Discussion**

The results from this analysis do not support a beneficial effect of bisphosphonate use on physical function outcomes in rehabilitation, as measured by the Barthel score. Although current bisphosphonate users achieved greater improvement in function during rehabilitation compared to previous users and never users, current users showed similar improvements to those who used bisphosphonates only after discharge from rehabilitation. For this latter group, drug exposure occurred only after discharge from rehabilitation and thus their functional improvement cannot be attributed to the effects of bisphosphonates. Our results do not therefore support a causal association between bisphosphonate therapy and functional improvement in this cohort. For post-discharge time to death and to next hospitalisation, our results suggest that previous exposure to bisphosphonates is a marker of increased risk of death or hospitalisation, but that ongoing exposure to bisphosphonates is associated with reduced hazard of death, and a less significant reduction in hazard of hospitalisation.

To our knowledge, this is the first study to examine the relationship between bisphosphonate use and functional outcomes during rehabilitation. The results of our analyses do not suggest a biological effect of bisphosphonates on biological pathways that might improve performance during rehabilitation – either via direct effects on musculoskeletal function or by reducing adverse events that interrupt rehabilitation. Rather, the results are consistent with current and future bisphosphonate use being a marker for unmeasured patient characteristics that are associated with better rehabilitation outcomes. Fitter, more robust patients who are perceived as having more to gain and longer to live may be more likely to be given bisphosphonates, and although the Barthel scores at admission to rehabilitation were similar across all four groups, there are other aspects of physical function and frailty that we were unable to measure directly using this routinely collected dataset.

A further potential confounder to address in this context is the frequent co-administration of calcium and vitamin D in routine treatment with bisphosphonates. UK clinical guidelines state that clinicians should ensure patients have an adequate intake of calcium and are vitamin D replete before prescribing bisphosphonates. The majority of older, frail patients in Scotland have low 25-hydroxyvitamin D levels – and our cohort are even more likely to have low levels given their prolonged stay in hospital. In the absence of vitamin D repletion, the increases in bone mineral density and anti-fracture efficacy associated with bisphosphonates, are attenuated21. Vitamin D has a direct effect on muscle function22, and therefore supplementation with this agent could confound the association between bisphosphonates and functional outcomes. We did not have data on 25-hydroxyvitamin D levels for this cohort, and thus we cannot completely adjust for the effect that vitamin D repletion might have had on the analyses. However, analysis of the large group of patients who had never received a bisphosphonate did not support an effect of calcium and vitamin D on either rehabilitation outcomes, survival or hospitalisation in this group, making this explanation less likely.

The results from analysis of time to death are broadly consistent with other randomised trial and observational data3,4,23,24 suggesting that bisphosphonates are associated with a lower risk of death. This is despite the fact that previous bisphosphonate use appears to be a risk marker for higher rates of death and hospitalisation. Such a finding, whilst paradoxical at first sight, is consistent with the fact that bisphosphonates will typically be used in those with a disease (osteoporosis) with major adverse consequences on fitness and function, which is itself associated with other life-shortening disease complexes (particularly cardiovascular disease5,25). Thus being prescribed bisphosphonates at some previous time may be a marker of a group at increased risk of death, but greater exposure to bisphosphonates themselves could still confer protective effects. Less striking results were seen on analysing time to hospitalisation or death; some previous studies have suggested lower death rates with bisphosphonate use, but not lower event rates for vascular disease. This would be consistent with our findings, and one possibility is that bisphosphonates might not reduce event rates, but might reduce the severity or impact of events on homeostatic function – i.e. they might enhance biological resilience26 via yet to be determined mechanisms. It is noteworthy that the more potent bisphosphonates are known to induce an acute-phase inflammatory response in some users2; inflammatory responses are also thought to contribute to the pathophysiology underlying phenomena such as ischaemic preconditioning in different organ systems27,28. Another possible mechanism is via anti-apoptotic effects; although bisphosphonates promote apoptosis of osteoclasts, they inhibit apoptosis of osteoblasts and osteoclasts, possibly via effects on pathways linked to connexin 43 29,30. Similar pathways are present in other tissues, including cardiomyocytes31, although the actions of bisphosphonates on apoptosis in human organ systems outwith bone remain to be elucidated.

Our study had a number of significant strengths. The dataset combined detailed health and functional outcomes data on a large set of patients undergoing rehabilitation in the real world, which enhances the generalisability of the data. Use of prescribing data from both before and after rehabilitation allowed us to test causal relationships in a way that would not have been possible without post-discharge prescribing data; these data enabled a more robust schema to be used to determine bisphosphonate treatment level (including use up to two years prior to rehabilitation and subsequent use), as opposed to a simple dichotomous indicator of treatment or no treatment at admission. Furthermore, the prescribing data comprises prescriptions encashed by patients and dispensed by pharmacists, rather than merely prescriptions written by physicians, thus the prescribing data may better reflect medication adherence than measures based on analysing numbers of prescriptions written. Combining detailed biochemical data allowed us to adjust analyses for albumin and renal function, both of which are important potential confounders.

A number of weaknesses deserve comment. The use of routine data limits the type of measures of frailty and function to those available from clinical practice when the data were collected, and missing data are frequent. Adherence was not measured directly; although prescriptions were dispensed we have no measure of ingestion of medication. Furthermore, we cannot account for medications available without prescription, which included low-dose calcium and vitamin D. Although intravenous bisphosphonates such as ibandronate and zoledronate were not used within our service (which included osteoporosis management) during the time period studied, we cannot exclude the possibility that a few patients received courses of intravenous bisphosphonates (e.g. to treat hypercalcaemia of malignancy) via oncology or other services; community prescribing data does not capture this use. We did not attempt to distinguish between different types of bisphosphonate; the majority of patients took once-weekly oral bisphosphonates. Although there may be different effects between different agents, the effects on mortality from trials appear to be broadly consistent in meta-analysis3. A further potential limitation is that we did not have access to 25-hydroxyvitamin D or PTH levels on patients; we are therefore unable to test whether vitamin D insufficiency or secondary hyperparathyroidism might modify the results of our analysis.

Bisphosphonates have a long duration of action on bone32, in part because they bind to hydroxyapatite crystals. The time course of biological effects in other organ systems is less clear33; our analysis assumes an extended duration of action after dosing, but this may not be the case for all potential biological effects. Similarly, the effects of bisphosphonates in this analysis are difficult to fully separate from any effects of calcium and vitamin D, both of which are known to have pleiotropic biological effects across multiple organ systems22. Finally, the cohort that we used comprised older patients selected for inpatient rehabilitation, and the cohort was exclusively white and mostly Northern European in ancestry. The findings from this cohort are not therefore necessarily generalizable to cohort comprising younger, fitter patients, unselected older patients or patients with different racial or ethnic background.

Our work suggests a number of avenues for future research. Replication of these findings in other cohorts would be of interest to ensure that an effect has not been missed by our analysis. Although the lack of evidence for a causal relationship between bisphosphonate use and improved rehabilitation outcomes does not support conducting trials in this specific area, the idea that bisphosphonates might be able to reduce death rates in older people by mitigating the deleterious impact of health events is an intriguing one, which merits further study. Studies designed specifically to examine this idea are needed, and should not be confined to patients with osteoporosis; both studies to explore possible biological mechanisms for the lower mortality seen in bisphosphonate users, and studies to test whether such an effect can be reproduced in those without osteoporosis, would be of considerable interest.

Funding: Scottish Collaboration for Public Health Research and Policy, grant SCPH/10

Acknowledgements: None

Author disclosure statement: None of the authors have any financial or other conflicts of interest to declare

**References**

1. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.

2. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007;357:1799-1809.

3. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95:1174-1181.

4. Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011;22:2551-2556.

5. Burnett JR, Vasikaran SD. Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 2002;39:203-210.

6. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 2005;98:467-484.

7. Ugur UA, Avcu F, Ozturk K. Bisphosphonates may retrieve endothelial function in vascular diseases similar to statins' effects. Eur J Haematol 2008;81:77-78.

8. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates – a systematic review. Clin Med Insights Endocrinol Diabetes 2012;5:47-54.

9. Lynch JE, Henderson NR, Ramage L, McMurdo ME, Witham MD. Association between statin medication use and improved outcomes during inpatient rehabilitation in older people. Age Ageing 2012;41:260-262.

10. Morandi A, Girard TD, Shintani A, Turco R, Guerini F, Torpilliesi T, Gentile S, Trabucchi M, Bellelli G. Association between statin use at admission to inpatient rehabilitation and functional status at discharge among older patients. Rejuvenation Res. 2014;17:490-495.

11. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 2009;5:265-272.

12. Burton LA, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging 2010;5:217-228.

13. Rossi P, Marzani B, Giardina S, Negro M, Marzatico F. Human skeletal muscle aging and the oxidative system: cellular events. Curr Aging Sci 2008;1:182-191.

14. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007;74:32-38.

15. Richards PJ, Amos N, Williams AS, Williams BD. Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology (Oxford) 1999;38:984-991.

16. Misra J, Mohanty ST, Madan S, Fernandes JA, Ebetino FH, Graham R, Russell G, Bellantuono I. Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects their Function. Stem Cells 2015 [epub ahead of print Dec 17th 2015; doi: 10.1002/stem.2255]

17. Witham MD, Ramage L, Burns SL, Gillespie ND, Hanslip J, Laidlaw S, Leslie CA, McMurdo ME. Trends in function and postdischarge mortality in a medicine for the elderly rehabilitation center over a 10-year period. Arch Phys Med Rehabil 2011;92:1288-1292.

18. Witham MD, Frost H, McMurdo M, Donnan PT, McGilchrist M. Construction of a linked health and social care database resource - lessons on process, content and culture. Inform Health Soc Care 2014 [Epub ahead of print March 20th 2014].

19. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud 1988;10:64-67.

20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.

21. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, Minisola S, Rossini M. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009;20:239-244.

22. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.

23. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011;22:983-991.

24. Center JR, Bliuc D, Nguyen ND, Eisman JA, Center JR. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011;96:1006-1014.

25. Lampropoulos CE, Papaioannou I, D'Cruz DP. Osteoporosis--a risk factor for cardiovascular disease? Nat Rev Rheumatol 2012;8:587-598.

26. Witham MD, Sayer AA. Biological resilience in older people - a step beyond frailty? Eur Geriatr Med 2015; 6: 101-102.

27. Alchera E, Dal Ponte C, Imarisio C, Albano E, Carini R. Molecular mechanisms of liver preconditioning. World J Gastroenterol 2010;16:6058-6067

28. Wang Y, Reis C, Applegate R 2nd, Stier G, Martin R, Zhang JH. Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke. Exp Neurol 2015 [Epub ahead of print Apr 18: doi: 10.1016/j.expneurol.2015.04.009]

29. Sadr-Eshkevari P, Ashnagar S, Rashad A, Dietz M, Jackowski J, Abdulazim A, Prochnow N. Bisphosphonates and connexin-43: a critical review of the evidence. Cell Commun Adhes 2014;21:241-247

30. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008;23:1712-1721.

31. Jeyaraman MM, Srisakuldee W, Nickel BE, Kardami E. Connexin 43 phosphorylation and cytoprotection in the heart. Biochim Biophys Acta 2012;1818:2009-2013.

32. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20.

33. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone 2011;49:42-49.

**Table 1. Baseline Details (n=2797)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Never used | Previous use | Current use | Subsequent use |
| N (%) | 2351 (84) | 124 (4) | 95 (3) | 227 (8) |
| Mean age (SD) | 84.2 (7.6) | 83.3 (6.9) | 84.7 (6.3) | 83.7 (7) |
| Male sex (%) | 1056 (45) | 24 (19) | 15 (16) | 58 (26) |
| Median length of stay (IQR) | 36 (46) | 33 (44) | 35 (46) | 38 (40) |
| Previous myocardial infarction (%) | 533 (23) | 38 (31) | 33 (35) | 41 (18) |
| Previous stroke (%) | 533 (23) | 17 (14) | 17 (18) | 41 (18) |
| Previous heart failure (%) | 370 (16) | 22 (18) | 14 (15) | 14 (6) |
| Previous hip fracture (%) | 188 (8) | 10 (8) | 11 (12) | 47 (21) |
| Previous COPD (%) | 299 (13) | 33 (27) | 20 (21) | 27 (12) |
| Previous diagnosis of cancer (%) | 290 (12) | 18 (15) | 7 (7) | 25 (11) |
| Diabetes mellitus (%) | 418 (18) | 20 (16) | 11 (12) | 37 (16) |
| Mean admission Barthel score (SD) | 10.4 (3.9) | 10.9 (3.4) | 10.5 (3) | 10.9 (3.2) |
| Median no of medications at admission (IQR) | 2 (5) | 3 (6) | 7 (4) | 2 (3) |
| Discharged to own home (%) | 1743 (74) | 97 (78) | 87 (92) | 202 (89) |
| Mean adjusted serum calcium (mmol/L) (SD) | 2.4 (0.1) | 2.4 (0.1) | 2.4 (0.1) | 2.4 (0.1) |
| Mean eGFR (ml/min) (SD) | 61.2 (23.7) | 68 (31.5) | 64.5 (28.2) | 65.2 (23.2) |
| Mean haemoglobin (g/dL) (SD) | 12.1 (1.9) | 11.7 (1.8) | 11.9 (2.2) | 11.8 (1.8) |
| Mean albumin (g/L) (SD) | 36.7 (4.9) | 36.0 (4.6) | 37.5 (4.5) | 36.9 (4.9) |

**Table 2. Association between Bisphosphonate use and change in Barthel Score during Rehabilitation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Never used | Previous use | Current use | Subsequent use |
| Unadjusted change in Barthel score (95% CI) | 3.8  (3.6-3.9) | 3.4  (2.8-4.0) | 5.2\*\*  (4.6-5.9) | 5.0\*\*  (4.6-5.5) |
| Adjusted change in Barthel score (95% CI) | 3.8  (3.6-3.9) | 3.4  (2.8-4.0) | 5.0 \*\*  (4.3-5.7) | 5.1\*\*  (4.6-5.5) |
| Unadjusted length of stay (95% CI) (days) | 57  (54.6-59) | 46  (36-57) | 51  (39-63) | 54  (47-62) |
| Adjusted length of stay (95% CI) (days) | 56  (54-58) | 50  (40-59) | 62  (50-73) | 54  (47-61) |

\**P*<.05, \*\**P*<.001 vs never users

Adjusted for: Baseline Barthel score, age, sex, comorbid disease (myocardial infarction, stroke, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, previous cancer), medication burden, recent hip fracture, baseline albumin, calcium, renal function (eGFR), and haemoglobin

Barthel score range 0 to 20; higher values indicate better function

**Table 3. Cox Regression Analysis for Time to Death or next Hospitalisation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Never used (n=2459) | Previous use (n=133) | Current use (n=100) | Subsequent use only (n=237) |
| Unadjusted hazard ratio for death (95% CI) | 1 | 1.39 (1.13 to 1.69) | 0.79 (0.62 to 1.00) | 0.50 (0.43 to 0.60) |
| Adjusted hazard ratio for death (95% CI) | 1 | 1.41 (1.15 to 1.73) | 1.00 (0.77 to 1.29) | 0.57 (0.48 to 0.67) |
| Unadjusted hazard ratio for next hospitalisation or death (95% CI) | 1 | 1.21 (1.00 to 1.45) | 1.20 (0.98 to 1.47) | 0.81 (0.71 to 0.93) |
| Adjusted hazard ratio for next hospitalisation or death (95% CI) | 1 | 1.18 (0.98 to 1.48) | 1.27 (1.01 to 1.59) | 0.88 (0.77 to 1.02) |
|  | Previous use vs no previous use | | Use post-discharge vs no use post-discharge | |
| Unadjusted hazard ratio for death (95% CI) | 1.13 (0.97 to 1.32) | | 0.56 (0.48 vs 0.65) | |
| Adjusted hazard ratio for death (95% CI) | 1.32 (1.11 to 1.56) | | 0.64 (0.55 to 0.73) | |
| Unadjusted hazard ratio for next hospitalisation or death (95% CI) | 1.23 (1.07 to 1.41) | | 0.89 (0.79 to 1.00) | |
| Adjusted hazard ratio for next hospitalisation or death (95% CI) | 1.24 (1.06 to 1.44) | | 0.95 (0.84 to 1.08) | |